Jyothi Nair

Bharat Biotech

Bharat Biotech International Limited is a multidimensional biotechnology company specializing in product-oriented research and development leading to the manufacture of vaccines and bio-therapeutics in Hyderabad, India. Bharat Biotech was established in the year 1996 by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella. Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. We seek to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets. Our significant R&D investments have yielded several breakthroughs including the world's 1st Eco-friendly recombinant Hepatitis-B vaccine (free of cesium chloride and Thiomersal).Rotavirus vaccine from a naturally attenuated strain,Typhoid Conjugate vaccine. Transparency and openness are central to our DNA. An uncompromising commitment to integrity differentiates us. Our clinical trials are known for their rigor and breadth. We also adopt the most comprehensive data integrity procedures to ensure that we capture, store and report data accurately. We are committed to provide affordable and innovative vaccines for healthier lives. Bharat Biotech launched India's first recombinant Epidermal Growth Factor (REGEN-D®) to combat diabetic foot ulcers, burns. Typbar TCV® is the world's first clinically proven conjugate Typhoid vaccine and received WHO-Prequalification in January 2018. ROTAVAC® was India's first and largest efficacy clinical trial on vaccines and Rotavac® received WHO-Prequalification in January 2018. Bharat Biotech Launches ROTAVAC 5D®- Lowest dose volume Rotavirus vaccine - ROTAVAC in the world launched in December 2019. COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech.